ストックスクリーナーアプリを入手
34.74
0.12%
0.04
アフターアワーズ：
34.74
前日終値:
$34.70
開ける：
$39.37
24時間の取引高:
937.64K
Relative Volume:
2.39
時価総額：
$1.91B
収益：
$597.40M
当期純損益:
$-15.51M
株価収益率:
47.59
EPS:
0.73
ネットキャッシュフロー:
$99.84M
1週間 パフォーマンス:
+1.05%
1か月 パフォーマンス:
+8.49%
6か月 パフォーマンス:
+12.68%
1年 パフォーマンス:
+41.91%
1日の値動き範囲:
$33.43
$39.37
1週間の範囲:
$33.43
$39.37
52週間の値動き範囲:
$23.05
$39.37
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
名前
Supernus Pharmaceuticals Inc
セクター
電話
301-838-2500
住所
9715 KEY WEST AVENUE, ROCKVILLE, MD
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-03 | 再開されました | Jefferies | Buy |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-04-13 | アップグレード | Jefferies | Hold → Buy |
| 2020-06-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 再開されました | Jefferies | Hold |
| 2019-11-08 | ダウングレード | Berenberg | Buy → Hold |
| 2019-11-07 | ダウングレード | Stifel | Buy → Hold |
| 2019-11-06 | ダウングレード | Jefferies | Buy → Hold |
| 2018-11-12 | 繰り返されました | B. Riley FBR | Buy |
| 2018-01-18 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | アップグレード | Janney | Neutral → Buy |
| 2017-11-08 | アップグレード | Stifel | Hold → Buy |
| 2017-10-19 | 開始されました | FBR & Co. | Buy |
| 2017-09-19 | ダウングレード | Stifel | Buy → Hold |
| 2017-07-17 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 開始されました | Janney | Neutral |
| 2017-06-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | アップグレード | Jefferies | Hold → Buy |
| 2015-11-05 | 繰り返されました | Northland Capital | Outperform |
| 2015-10-28 | 開始されました | Northland Capital | Outperform |
すべてを表示
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
Earnings call: Supernus Pharmaceuticals reported a significant increase in total revenue - Investing.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High Following Earnings Beat - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highli - GuruFocus.com
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates - MSN
Supernus Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Supernus Pharmaceuticals Q3 2024 Earnings: EPS of $0.69 Beats Es - GuruFocus.com
Supernus Announces Third Quarter 2024 Financial Results - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results - MarketBeat
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals (FRA:S49) PE Ratio : 387.50 (As of Nov. 04, 2024) - GuruFocus.com
Supernus: Q3 Earnings Snapshot - The Washington Post
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
(SUPN) On The My Stocks Page - Stock Traders Daily
Macquarie Group Ltd Adjusts Stake in Supernus Pharmaceuticals Inc - GuruFocus.com
Stephens Investment Management Group LLC Buys 33,710 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Dimensional Fund Advisors LP Expands Stake in Supernus Pharmaceu - GuruFocus.com
Supernus Presents Promising Data from Open-Label Phase 2a - GlobeNewswire
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - Yahoo Finance
Supernus Pharmaceuticals reports rapid depression treatment response By Investing.com - Investing.com Australia
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk - Simply Wall St
Supernus Pharmaceuticals reports rapid depression treatment response - Investing.com India
Supernus Pharmaceuticals (SUPN) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Attention Deficit Hyperactivity Disorder Market Projected - openPR
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - The Manila Times
Supernus Pharmaceuticals to Host Conference Call and - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 12-Month HighTime to Buy? - MarketBeat
Exchange Traded Concepts LLC Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus’ depression drug improved symptoms in two hours in Phase IIa study - Clinical Trials Arena
Supernus stock holds Buy rating on MDD trial data By Investing.com - Investing.com UK
Supernus Announces Promising Data from Open-Label Phase 2a - GlobeNewswire
Supernus reports Phase 2a data for SPN-820, stock climbs 6% - MSN
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with - The Bakersfield Californian
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - StockTitan
SUPN (Supernus Pharmaceuticals) 3-Year EPS without NRI Grow - GuruFocus.com
(SUPN) Trading Signals - Stock Traders Daily
Millennium Management LLC Buys 128,743 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder - The Manila Times
Supernus Pharmaceuticals to Host Webcast to Review - GlobeNewswire
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Healthcare of Ontario Pension Plan Trust Fund Buys Shares of 40,000 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Marshall Wace LLP Acquires Shares of 73,519 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
(SUPN) Technical Data - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Bank of Montreal Can - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Armistice Capital LLC Has $141.03 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Pulling back 3.6% this week, Supernus Pharmaceuticals' NASDAQ:SUPN) five-year decline in earnings may be coming into investors focus - Simply Wall St
Busy Philipps Encourages Women to Take Charge of Their ADHD - GlobeNewswire
Supernus Pharmaceuticals Inc (SUPN) 財務データ
収益
当期純利益
現金流量
EPS
0.88%
0.42%
大文字化:
|
ボリューム (24 時間):